SOAT1 and carcinoma: In vitro, ruxolitinib treatment blocked STAT phosphorylation and strongly decreased both proliferation of NK cells and the killing capability of NK cells against carcinoma cells, indicating that JAK/STAT pathway inhibition impairs the anti-tumor potential of NK cells.